Study highlights the efficacy and safety of tildrakizumab in improving physical, psychological, and social aspects of quality ...

The company had $583.3 million in cash as of September 30th of 2024; Enough cash to fund its operations until the end of 2027 ...

The use of risankizumab after poor response to 2 interleukin-17 inhibitors, secukinumab, and ixekizumab, was safe and effective in plaque psoriasis.

Researchers identified 3 distinct PsA phenotype clusters, emphasizing the importance of PsO severity in treatment decision making.

UCB announced that a single-injection 2 mL prefilled syringe and autoinjector, each containing 320 mg of BIMZELX is now available.

Formycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Otulfi ® received MHRA approval for both subcutaneous and intravenous formulations, to ...

People whose childhoods featured abuse, neglect, or domestic abuse are more likely to be at risk of developing rheumatoid ar ...

Patients with cutaneous lupus erythematosus (CLE), an autoimmune disease that causes skin inflammation, have a higher risk ...

Researchers identify a pathogenic subset of CD8+ memory T-cells that promote airway tissue inflammation and recurrent ...

If perpetually cold hands and feet weren’t clear tip-offs that we’re now in winter’s grasp, perhaps a flurry of dry, flaky skin has driven it home. Rough, itchy patches are ...